ENXTPA:GNRO

Stock Analysis Report

Executive Summary

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases.

Snowflake

Fundamentals

High growth potential with adequate balance sheet.

Risks

  • GeNeuro is covered by less than 3 analysts.

Share Price & News

How has GeNeuro's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

-7.8%

ENXTPA:GNRO

-0.3%

FR Biotechs

-0.2%

FR Market


1 Year Return

-41.5%

ENXTPA:GNRO

-40.4%

FR Biotechs

-1.7%

FR Market

GNRO underperformed the Biotechs industry which returned -39.3% over the past year.

GNRO underperformed the Market in France which returned -0.8% over the past year.


Share holder returns

GNROIndustryMarket
7 Day-7.8%-0.3%-0.2%
30 Day12.8%-8.0%-3.9%
90 Day-13.8%-16.6%-0.7%
1 Year-41.5%-41.5%-40.3%-40.4%1.6%-1.7%
3 Year-53.3%-53.3%-57.5%-57.7%39.6%26.0%
5 Yearn/a-50.3%-51.3%53.8%31.0%

Price Volatility Vs. Market

How volatile is GeNeuro's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is GeNeuro undervalued based on future cash flows and its price relative to the stock market?

>50%

Discount to future cash flow value


Intrinsic Value Based on Future Cash Flows

GeNeuro's share price is below the future cash flow value, and at a moderate discount (> 20%).

GeNeuro's share price is below the future cash flow value, and at a substantial discount (> 40%).


Price Based on Earnings

GeNeuro is loss making, we can't compare its value to the FR Biotechs industry average.

GeNeuro is loss making, we can't compare the value of its earnings to the France market.


Price Based on Expected Growth

Unable to calculate PEG ratio for GeNeuro, we can't assess if its growth is good value.


Price Based on Value of Assets

GeNeuro is overvalued based on assets compared to the FR Biotechs industry average.


Next Steps

Future Growth

How is GeNeuro expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

42.3%

Forecasted annual earnings growth


Earnings and Revenue Growth Estimates


Future Annual Growth Analysis

GeNeuro's revenue is expected to grow significantly at over 20% yearly.

GeNeuro's earnings are expected to grow significantly at over 20% yearly.

GeNeuro's revenue growth is expected to exceed the France market average.

GeNeuro's earnings growth is expected to exceed the France market average.

GeNeuro's earnings growth is expected to exceed the low risk savings rate of 0.7%.


Earnings per Share Growth Estimates


Future Return on Equity

Unable to establish if GeNeuro will efficiently use shareholders’ funds in the future without estimates of Return on Equity.


Next Steps

Past Performance

How has GeNeuro performed over the past 5 years?

-23.6%

Historical annual earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

GeNeuro does not make a profit and their year on year earnings growth rate was negative over the past 5 years.

Unable to compare GeNeuro's 1-year earnings growth to the 5-year average as it is not currently profitable.

Unable to compare GeNeuro's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.


Return on Equity

It is difficult to establish if GeNeuro has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.


Return on Assets

It is difficult to establish if GeNeuro has efficiently used its assets last year compared to the FR Biotechs industry average (Return on Assets) as it is loss-making.


Return on Capital Employed

It is difficult to establish if GeNeuro improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.


Next Steps

Financial Health

How is GeNeuro's financial position?


Financial Position Analysis

GeNeuro is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.

GeNeuro's cash and other short term assets cover its long term commitments.


Debt to Equity History and Analysis

GeNeuro's level of debt (3.4%) compared to net worth is satisfactory (less than 40%).

The level of debt compared to net worth has been reduced over the past 5 years (17.9% vs 3.4% today).


Balance Sheet

Low level of unsold assets.

Debt is covered by short term assets, assets are 66.9x debt.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

GeNeuro has less than a year of cash runway based on current free cash flow.

GeNeuro has less than a year of cash runway if free cash flow continues to grow at historical rates of 60.6% each year.


Next Steps

Dividend

What is GeNeuro's current dividend yield, its reliability and sustainability?


Dividend Yield and Payments Analysis

Unable to evaluate GeNeuro's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.

Unable to evaluate GeNeuro's dividend against the top 25% market benchmark as the company has not reported any payouts.

Unable to perform a dividend volatility check as GeNeuro has not reported any payouts.

Unable to verify if GeNeuro's dividend has been increasing as the company has not reported any payouts.


Current Payout to Shareholders

Unable to calculate sustainability of dividends as GeNeuro has not reported any payouts.


Future Payout to Shareholders

No need to calculate the sustainability of GeNeuro's dividends in 3 years as they are not expected to pay a notable one for France.


Next Steps

Management

What is the CEO of GeNeuro's salary, the management and board of directors tenure and is there insider trading?

3.6yrs

Average management tenure


CEO

Jesús Martin-Garcia (56yo)

3.6yrs

Tenure

€694,000

Compensation

Mr. Jesús Martin-Garcia is the Founding Partner, General Partner, and Director of Eclosion SA. He serves at GeNeuro SA as the Chairman of the Board since February 06, 2006 and Chief Executive Officer since ...


CEO Compensation Analysis

Jesús's remuneration is higher than average for companies of similar size in France.

Jesús's compensation has been consistent with company performance over the past year, both up more than 20%.


Management Age and Tenure

3.6yrs

Average Tenure

55yo

Average Age

The tenure for the GeNeuro management team is about average.


Board Age and Tenure

4.3yrs

Average Tenure

62.5yo

Average Age

The tenure for the GeNeuro board of directors is about average.


Insider Trading

No 3 month open market individual insider trading information.


Ownership Breakdown


Management Team

  • Miguel Payró (54yo)

    Chief Financial Officer

    • Tenure: 3.7yrs
  • Hervé Perron (60yo)

    Chief Scientific Officer

    • Tenure: 0.0yrs
  • Jesús Martin-Garcia (56yo)

    Chairman & CEO

    • Tenure: 3.6yrs
    • Compensation: €694.00k
  • François Curtin (54yo)

    COO & Interim Chief Medical Officer

    • Tenure: 10.6yrs
  • Thomas Rückle

    Senior VP & Head of Pre-Clinical Development

    • Tenure: 2.6yrs

Board Members

  • Michel Dubois (76yo)

    Independent Director

    • Tenure: 11.1yrs
    • Compensation: €22.20k
  • Gordon Francis (69yo)

    Independent Director

    • Tenure: 4.4yrs
    • Compensation: €31.10k
  • Marc Bonneville (59yo)

    Independent Director

    • Tenure: 3.8yrs
  • Giacomo Di Nepi (66yo)

    Independent Director

    • Tenure: 4.1yrs
    • Compensation: €23.30k
  • Eric Falcand (57yo)

    Independent Director

    • Tenure: 3.8yrs
  • Christophe Guichard (49yo)

    Director

    • Tenure: 3.8yrs
  • Jesús Martin-Garcia (56yo)

    Chairman & CEO

    • Tenure: 3.6yrs
    • Compensation: €694.00k
  • Jean-Jacques Laborde (73yo)

    Independent Director

    • Tenure: 5.5yrs

Company Information

GeNeuro SA's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: GeNeuro SA
  • Ticker: GNRO
  • Exchange: ENXTPA
  • Founded: 2006
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €50.006m
  • Shares outstanding: 14.58m
  • Website: https://www.geneuro.ch

Number of Employees


Location

  • GeNeuro SA
  • 3 chemin du Pré-Fleuri
  • Plan-les-Ouates
  • Geneva
  • 1228
  • Switzerland

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
GNROENXTPA (Euronext Paris)YesClass C Common SharesFREURApr 2016
GEMDB (Deutsche Boerse AG)YesClass C Common SharesDEEURApr 2016
0RHKLSE (London Stock Exchange)YesClass C Common SharesGBEURApr 2016
GNRR.FOTCPK (Pink Sheets LLC)YesClass C Common SharesUSUSDApr 2016

Biography

GeNeuro SA, a clinical-stage biopharmaceutical company, develops drugs for the treatment of neurodegenerative and autoimmune diseases. Its lead therapeutic candidate is temelimab, a monoclonal antibody, wh ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/08/20 22:02
End of Day Share Price2019/08/20 00:00
Earnings2018/12/31
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.